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ABSTRACT
Metastatic prostate cancer represents a yet unsolved clinical problem due 
to the high frequency of relapse and treatment resistance. Understanding the 
pathways that lead to prostate cancer progression is an important task to prevent 
this deadly disease. The ETS transcription factor ESE3/EHF has an important role 
in differentiation of human prostate epithelial cells. Loss of ESE3/EHF in prostate 
epithelial cells determines transformation, epithelial-to-mesenchymal transition 
(EMT) and acquisition of stem-like properties. In this study we identify IL-6 as a direct 
target of ESE3/EHF that is activated in prostate epithelial cells upon loss of ESE3/
EHF. ESE3/EHF and IL-6 were significantly inversely correlated in prostate tumors. 
Chromatin immunoprecipitation confirmed binding of ESE3/EHF to a novel ETS binding 
site in the IL-6 gene promoter. Inhibition of IL-6 reverted transformation and stem-
like phenotype in tumorigenic ESE3/EHF knockdown prostate epithelial cell models. 
Conversely, IL-6 stimulation induced malignant phenotypes, stem-like behavior and 
STAT3 activation. Increased level of IL-6 was observed in prostatospheres compared 
with adherent bulk cancer cells and this was associated with stronger activation 
of STAT3. Human prostate tumors with IL-6 elevation and loss of ESE3/EHF were 
associated with STAT3 activation and displayed upregulation of genes related to cell 
adhesion, cancer stem-like and metastatic spread. Pharmacological inhibition of IL-6/
STAT3 activation by a JAK inhibitor restrained cancer stem cell growth in vitro and 
inhibited self-renewal in vivo. This study identifies a novel connection between the 
transcription factor ESE3/EHF and the IL-6/JAK/STAT3 pathway and suggests that 
targeting this axis might be preferentially beneficial in tumors with loss of ESE3/EHF.
INTRODUCTION
Prostate cancer remain the most common malignancy 
and the second most frequent cause of cancer-related 
mortality in men in developed countries [1, 2]. Metastatic 
prostate cancer represents a yet unsolved clinical problem 
due to the high frequency of relapse and treatment 
resistance. Understanding the pathways that lead to 
prostate cancer progression in primary prostate tumors is an 
important task to prevent this deadly disease. Several studies 
have provided evidence of the presence of tumor-initiating 
stem-like cancer cells with high self-renewing properties 
in human cancers, including prostate cancer [3–5]. Cancer 
stem cells (CSCs) with acquired stem-like properties can 
originate from transformation of normal tissue/adult stem 
cells or from more differentiated progenitor cells [6, 7]. 
CSCs within the primary tumors are likely a major source 
of tumor heterogeneity, disease progression and treatment 
failure. The cancer stem cell model postulates a hierarchical 
organization of cells such that only a small subset is 
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responsible for tumorigenesis in primary tumors. On the 
other hand, several factors contribute to the solid tumor 
heterogeneity including genetic mutations and epigenetic 
changes and the presence or absence of a cellular hierarchy. 
Thus, understanding the mechanisms controlling the 
expansion and maintenance of prostate CSCs could be an 
important step toward development of more effective CSC-
directed strategies for treatment of prostate cancer. 
ETS transcription factors are main elements in 
differentiation and developmental programs in many 
tissues. Expression of ETS factors is tightly regulated 
according to tissue-specific and time-dependent programs 
[8, 9]. Deregulated expression of ETS factors has oncogenic 
consequences on tissue developmental programs and is one 
of the most frequent findings in human tumors. About 50% 
of prostate cancers exhibit gene rearrangements and ectopic 
expression of ETS genes, like ERG and ETV1 [10–13]. 
ESE3/EHF is an ETS factor expressed in normal epithelial 
cells, including prostate epithelial cells [9]. Notably, ESE3/
EHF ranks among most highly expressed transcription 
factors [14]. Previously we reported that ESE3/EHF is 
frequently downregulated in prostate tumors and that its 
loss is associated with robust inflammatory gene signatures 
[15, 16]. Furthermore, we showed that ESE3/EHF controls 
the differentiation program of prostate epithelial cells and 
its loss alters cell differentiation and conferred a CSC-
like phenotype along with tumor-initiating and metastatic 
capability [17]. We found that ESE3/EHF controls a large 
network of targets transcriptionally, inducing genes related to 
epithelial cell differentiation and repressing genes connected 
with self-renewal and CSC phenotype [17]. Relevantly, we 
have recently shown that ESE3/EHF directly controls the 
level and activity of distinct components of the Lin28/let-
7 axis, a key pathway involved in stem cell biology and 
expansion of cancer stem cell compartment [18].
IL-6 is a cytokine involved in many physiologic and 
pathophysiologic processes. IL-6 signaling leads to activation 
of JAK/STAT pathway and recent reports demonstrated that 
STAT3 activation occurrs frequently in metastatic prostate 
cancer [19]. While the oncogenic role of IL-6 has been 
widely investigated, little is known about factors regulating 
IL-6, particularly at the transcriptional level. Understanding 
the factors regulating IL-6 expression might be relevant 
for novel approach targeting its activation. In these studies 
we identify IL-6 as a novel direct target of ESE3/EHF. 
These data establish that repression of IL-6 is an important 
mechanism by which ESE3/EHF restrains stemness and 
tumor progression. This opens new perspective to target 
aggressive tumors with IL-6 elevation and loss of ESE3/EHF.
RESULTS
IL-6 is inversely correlated to ESE3/EHF in 
prostate cells and tumors
In an effort to understand the role of ESE3/EHF 
in restraining stem-like phenotypes, we observed that 
in a panel of human prostate cancer cells IL-6 level 
was inversely correlated to ESE3/EHF and increased 
gradually from less aggressive, androgen-dependent 
and ESE3/EHF positive LNCaP to the  more aggressive 
androgen-independent and ESE3/EHF negative DU145 
cells (Figure 1A upper and lower panels). Moreover, IL-6 
was significantly elevated in prostate epithelial cells with 
stable ESE3/EHF knockdown at the mRNA and protein 
level suggesting that ESE3/EHF could maintain IL-6 
repressed in normal epithelial cells (Figure 1B and 1C). In 
keeping with this hypothesis, IL-6 level was significantly 
elevated in ESE3low tumors (p < 0.01) compared to normal 
prostate [16]. To determine whether the link between 
ESE3/EHF and IL-6 observed in our cell line models was 
seen also in clinical samples, we analyzed gene expression 
data from two large (n = 545 and n = 131, respectively) 
human prostate cancer patients datasets [20, 21]. We 
found a significant inverse correlation between ESE3/
EHF and IL-6 expression in human tumors (Figure 1D–
1E). Notably, the inverse correlation between ESE3/EHF 
and IL-6 was also observed in metastatic prostate tumors 
(Figure 1F). Collectively, these data suggested that IL-6 
could be a transcriptional target of ESE3/EHF. 
ESE3/EHF transcriptionally represses IL-6
To better define the relationship between ESE3/
EHF and IL-6, we scanned the IL-6 gene promoter for 
ETS binding sites (EBS). Computational analysis showed 
multiple highly scored EBS corresponding to the consensus 
EHF motif in the promoter region (Figure 2A). To test 
whether ESE3/EHF bound to the promoter and controlled 
IL-6 transcription, we selected a high-confidence 
EBS which was also nearest (-550/-557 bp) to the 
transcription starting site (TSS) and performed chromatin 
immunoprecipitation (ChIP). We found that ESE3/EHF 
bound to the IL-6 promoter in LNCaP cells that express 
high level of ESE3/EHF (Figure 2B left panel). Consistent 
with a repressive function on the IL-6 promoter, we 
found enrichment of repressive (H3K9me and H3K27me) 
histone marks in LNCaP cells (Figure 2B right panel). The 
transcriptional effect of ESE3/EHF on IL-6 was further 
assessed by measuring IL-6 promoter activity in DU145 
cells, which do not express endogenous ESE3/EHF. 
Activity of the IL-6 promoter reporter was significantly 
reduced by transient expression of ESE3/EHF in DU145 
cells, consistent with transcriptional repression of the gene 
by ESE3/EHF (Figure 2C). Collectively these data support 
that ESE3/EHF directly control IL-6 transcription and 
maintains the gene under a repressive status.
IL-6 is a mediator of prostate epithelial cell 
transformation and stem cell properties upon 
loss of ESE3/EHF
To understand the contribution of IL-6 to the 
transformed phenotype observed in prostate epithelial 
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cells upon loss of ESE3/EHF, we transiently knockdown 
IL-6 by siRNA in ESE3KD-PrECs and ESE3KD 
RWPE- 1 cells for 48 h and assessed the consequences 
on the cell phenotype. IL-6 knockdown was evaluated 
at mRNA level by qRT-PCR (Figure 3A). We observed 
a significant decrease in the colony number in soft agar 
in ESE3KD cells transfected with siRNA targeting 
IL-6 compared to control (siGL3) transfected cells 
(Figure 3B). Moreover, tumor sphere formation 
efficiency (SFE) was also significantly reduced in siIL-6 
treated cells compared to control cells suggesting an 
impact on the cancer stem-like compartment (Figure 3C). 
To determine whether IL-6 ablation also reversed target 
gene activation observed in ESE3KD cells, we evaluated 
the expression of selected gene markers. We observed 
a significant reduction of the level of STAT3, BMI-1, 
NANOG and POU5F1 indicating that IL-6 activation 
contributes to the activation of these target genes upon 
loss of ESE3/EHF (Figure 3D). Collectively, these 
data indicate that knockdown of IL-6 in ESE3KD cells 
Figure 1: ESE3/EHF and IL-6 expression are inversely correlated. (A) IL-6 (top) and ESE3/EHF (bottom) mRNA levels 
evaluated by qRT-PCR in indicated PCa cell lines. β-actin was used as reference for loading control. Data are presented as fold change 
relative to LNCaP cells. (B) IL-6 (top) and ESE3/EHF (bottom) mRNA levels evaluated by qRT-PCR in ESE3KD cell line models. β-actin 
was used as reference for loading control. Data are presented as fold change relative to PrECs and RWPE-1 cells. (C) Immunoblots of 
IL-6 in indicated cell lines. IL-6/Tubulin ratio determined by band intensity is reported. (D) ESE3/IL-6 correlation analysis. Table shows 
correlation coefficient and p value in indicated datasets. (E–F). Pearson distribution plots showing significant inverse correlation between 
IL-6 and ESE3/EHF in human primary (E) and metastatic prostate tumors (F). P values were determined using t-test. *P < 0.05; **P < 0.01. 
Data are representative of three independent experiments with at least three replicates per experiment. 
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is sufficient to reverse the transforming and the stem-
like phenotype acquired upon loss of ESE3/EHF. Thus, 
activation of the IL-6 pathway is an important mediator 
of the effects observed in ESE3KD cells and targeting 
IL-6 could be a useful strategy in the context of low 
ESE3/EHF expressing prostate tumors. 
IL-6 induces transformation and cancer stem-
like phenotypes
To further understand the consequences of IL-6 
upregulation, we exposed normal PrECs and RWPE-1 and 
corresponding ESE3KD cells to IL-6 stimulation. We observed 
that IL-6 treatment significantly increased tumor sphere 
formation in normal (PrECs) and ESE3KD prostate epithelial 
cells compared to vehicle treated cells (Figure 4A–4B). 
Consistently, canonical CSC markers like Lin28A, Lin28B, 
BMI-1, NANOG and POU5F1 were also significantly induced 
in both normal and ESE3KD cells compared to vehicle treated 
cells (Figure 4C–4D). IL-6 and STAT3 mRNA level were 
also induced after IL-6 treatment (Figure 4C–4D). Overall, 
the response to IL-6 was stronger in ESE3KD compared to 
the normal prostate epithelial cells. Flow cytometry analysis 
revealed that IL-6 stimulation induced a robust elevation of 
pSTATyr705 in ESE3KD-PrECs and ESE3KD-RWPE-1 
in comparison to cells treated with vehicle (Figure 4E). 
Collectively these data support a role of IL-6 in expanding the 
prostate cancer stem-like phenotype and suggest that ESE3/
EHF controls both basal and IL-6 induced STAT3 response. 
Low level of ESE3/EHF in the cell context and human tumors 
might render cells hypersensitive to IL-6 stimulation. 
Targeting IL-6/STAT3 activation by JAK2 
inhibitors inhibits stemness and self–renewal 
properties in ESE3KD-PrECs in vivo
IL-6 could play a role in transforming prostate 
epithelial cells by activating the JAK/STAT3 pathway. 
Consistent with this hypothesis, the level of IL-6 was 
significantly enriched in the CSC compartment in 
ESE3KD-PrECs in comparison to the adherent counterpart 
(Figure 5A). Intriguingly, we also found that pSTAT3 
Tyr705 was increased in ESE3KD prostatospheres 
compared to adherent counterpart cells by ICC staining 
(Figure 5B) and by flow cytometry (Figure 5C) in 
ESE3KD-PrECs and RWPE-1 cells. 
Thus, targeting the JAK/STAT3 pathway could 
antagonize stemness and self-renewal phenotypes in these 
cells. To test this, we used NVP-BSK805, a potent and 
selective JAK2 inhibitor, to inhibit STAT3 phosphorylation 
at Tyr705. NVP-BSK805 treatment significantly reduced 
prostatosphere formation in adherent ESE3KD-PrECs and 
Figure 2: ESE3/EHF transcriptionally represses IL-6. (A) Predicted ETS binding sites (EBS) in the human IL-6 promoter (left). 
Position relative to the transcription start site (TSS) of the gene, sequence, corresponding scores (right) and EHF scanned motif logo 
(lower left). (B) Binding of ESE3/EHF to the IL-6 promoter (left panel) and chromatin marks (right panel) determined by chromatin 
immunoprecipitation (ChIP) in LNCaP cells. (C) Transcriptional activity of IL-6 promoter reporters in control (pcDNA) and stably ESE3/
EHF expressing (pESE3) DU145 cells evaluated by dual luciferase assay. P values were determined using t-test. *P < 0.05; **P < 0.01. 
Data are representative of three independent experiments.
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ESE3KD-RWPE-1 cells (Figure 6A and 6B). Next, we 
tested the ability of NVP-BSK805 to inhibit tumorigenicity 
and self-renewal of ESE3KD-PrECs prostatosphere-
derived tumor xenografts (ESE3KD-PrECs-xeno) 
in vivo. ESE3KD-PrECs xenografts were grown for the 
first generation in vivo. Then, the tumors were explanted, 
dissociated and re-engrafted subcutaneously. Treatment 
was initiated 21 days after the engraftment and continued 
for 2 weeks (Figure 6C). Notably, in vivo treatments 
significantly reduced the growth rate and size of the 
prostatosphere-derived tumor xenografts (Figure 6D– 6E). 
Notably, the level of IL-6 was elevated in G1-G3 
prostatosphere-derived tumor xenografts being higher 
than those observed in ESE3KD adherent cells in culture 
(Figure 6F). Importantly,IL-6 was significantly reduced 
by the treatment with the JAK2 inhibitor (Figure 6G). 
Figure 3: IL-6 is a mediator of prostate epithelial cell transformation and stem cell properties upon loss of ESE3/EHF. 
(A) Knockdown efficiency of IL-6 evaluated by qRT-PCR following transfection with siRNAs targeting IL-6 in ESE3KD-PrECs (top) 
and RWPE-1 cells (bottom). (B–C) Colony formation (B) and sphere forming efficiency (C) in ESE3KD-PrECs and ESE3KD-RWPE-1 
following transfection of IL-6 siRNA. (D) STAT3 and canonical CSC marker mRNA level evaluated by qRT-PCR in ESE3KD-PrECs (left) 
and ESE3KD-RWPE-1 (right) following transfection with siRNAs targeting IL-6. β-actin was used as reference gene. Data are presented 
as fold change relative to control siGL3. P values were determined using t-test. *P < 0.05; **P < 0.01. Data are representative of three 
independent experiments.
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Figure 4: IL-6 induces transformation and cancer stem-like phenotypes in normal and more significantly in ESE3KD 
prostate epithelial cells. (A–B) Sphere forming efficiency (SFE) in PrECs and ESE3KD-PrECs (A) and in RWPE-1 and ESE3KD-
RWPE-1 (B) cells after IL-6 treatment in vitro. (C–D) mRNA levels of STAT3, IL-6 and indicated genes evaluated by qRT-PCR in PrECs 
and ESE3KD-PrECs (left) (C) and in RWPE-1 and ESE3KD-RWPE-1 cells (right) (D) following 4 hours of treatments in vitro with IL-6 
(50 ng/ml) or DMSO as control (CTRL). Data are presented as fold change relative to control (CTRL) cells. (E) Flow cytometry analysis 
of STAT3-Tyr705 staining following IL-6 treatment of control PrECs and ESE3KD-PrECs (upper) and RWPE-1 and  ESE3KD-RWPE-1 
(lower) cells. Percentages of positive cells are shown. P values were determined using t-test. *P < 0.05; **P < 0.01. Data are representative 
of three independent experiments.
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Furthermore, when we explanted the tumors and evaluated 
ex vivo the SFE we found that the prostatosphere forming 
ability was significantly compromised in cells derived 
from NVP-BSK805 treated xenografts compared to control 
xenografts, suggesting that the CSC-like compartment 
was affected by the treatment (Figure 6H). Consistent 
with a specific inhibition of the JAK-STAT3 pathway, 
flow cytometry analysis revealed significant reduction of 
pSTAT3 in tumor xenografts treated with NVP-BSK805 
(Figure 6I). Collectively, these data suggest that the 
expansion of stem-like cancer cells in tumor xenografts 
from ESE3KD-PrECs was associated with elevation of 
IL-6 and consequent activation of JAK/STAT3 and that it 
could be efficiently targeted by JAK/STAT3 inhibitors. 
IL-6 elevation and loss of ESE3/EHF are 
associated with STAT3 activation and enrichment 
of aggressive features in human prostate tumors
To further understand the clinical relevance of our 
data and verify the association between loss of ESE3/
EHF, IL-6 upregulation and STAT3 activation with 
aggressive features in prostate tumors, we selected a 
group of tumors characterized by high level of IL-6 and 
low level of ESE3/EHF (IL-6high/ESE3low) (Figure 7A) in 
a large primary prostate tumor dataset [21]. By applying 
differential gene expression analysis we extracted a gene 
signature comparing the expression profile of the IL-6high/
ESE3low (n = 51) with the remaining tumors (n = 495). 
The IL-6high/ESE3low tumors displayed a robust signature 
with several genes up and downregulated. We analyzed 
the top overexpressed genes (≥ 2 fold) in the IL-6high/
ESE3low signature by ChIP Enrichment Analysis (CHEA) 
and found a significant enrichment of STAT3 targets 
among other transcription factors (Figure 7B). Relevantly, 
the EBS sites were also significantly over-represented 
among the genes in the IL-6high/ESE3low signature 
(Figure 7C) suggesting that the genes extracted could 
be direct targets of EHF. Functional annotation analysis 
of the genes activated in IL-6high/ESE3low signature by 
Metacore supported enrichment of inflammatory genes 
and genes related to cell adhesion and metastatic spread 
(Figure 7D).To further understand the functional relevance 
of this signature we performed gene set enrichment 
analysis (GSEA) (Figure 7E). This analysis revealed that 
the IL-6high/ESE3low tumors were significantly enriched 
of genes attenuated in IL-6 deprivation (Croonquist_
IL-6_DN), underlying the accuracy of our approach 
in extracting relevant IL-6 targets in prostate tumors. 
Moreover, the IL- 6high/ESE3low tumors were also enriched 
of an ensemble of genes encoding extracellular matrix and 
extracellular matrix-associated proteins (Naba_Matrisome), 
genes conferring migratory and metastatic properties. 
Intriguingly, there was also enrichment of genes acting as a 
barrier for senescence, a pathway opposing the induction of 
a cancer stem cell phenotype. Collectively, these findings 
supported the activation of the IL-6/STAT3 pathway and 
aggressive cancer stem-like phenotype in IL-6high/ESE3low 
tumors and suggested that these tumors could be targeted 
by therapy opposing this pathway.
DISCUSSION
In this study we report a link between the tumor 
suppressor ESE3/EHF and IL-6. Specifically, loss of 
ESE3/EHF leads to upregulation of IL-6 and activation 
Figure 5: IL-6 elevation and STAT3 induction in cancer stem-like compartment of ESE3KD prostate epithelial cells. 
(A) IL-6 mRNA level evaluated by qRT-PCR in adherent and prostatosphere cells derived from ESE3KD-PrECs (top) and ESE3KD-
RWPE-1 (bottom) cells. Data are presented as fold change relative to the corresponding adherent cells. (B) ICC staining for STAT3 total 
and pSTAT3-Tyr705 for adherent cells and prostatospheres derived from ESE3KD-PrECs (upper) and ESE3KD-RWPE-1 (lower) cultures. 
(C) Flow cytometry analysis of STAT3-Tyr705 staining for indicated cells. Percentages of positive cells are shown.
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Figure 6: Targeting IL-6/STAT3 activation by JAK2 inhibitors reverses stemness and self–renewal properties in vivo. 
(A) Experimental plan of JAK2 inhibitor (NVP) treatment of prostatospheres derived from ESE3KD-PrECs cells during SFA. (B) SFE of 
ESE3KD-PrECs and ESE3KD-RWPE-1 cells upon treatment described in A. (C) Experimental plan of the treatment with JAK2 inhibitor 
in vivo. Prostatospheres obtained from SFA were dissociated and injected subcutaneously in NSG mice (n = 4/group). Tumors formed by 
ESE3KD-PrECs prostatospheres cells (G1 xeno) were dissociated and re-implanted (2 × 105 cells/site) in NSG mice (n = 4/group) for 
two consecutive generations (G2 xeno and G3 xeno). Treatment was initiated 21 days post-engraftment of the G3 xeno and continued as 
indicated (lower panel). (D–E) Tumor growth determined by caliper (D) and tumor weight (E) of G3 xeno following treatment as described 
in C. (F) IL-6 evaluation by qRT-PCR in ESE3KD prostatospheres and G1-G3 xeno. (G) IL-6 evaluation by qRT-PCR in control (CTRL) 
and following treatment with JAK2 inhibitor. (H–I). SFE ex vivo (H) and flow cytometry analysis of STAT3-Tyr705 staining (I) following 
JAK2 treatment described in C. P values were determined using t-test. *P < 0.05; **P < 0.01. Data are representative of three independent 
experiments with at least three replicates per experiment. Percentages of positive cells are shown.
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of the JAK/STAT3 pathway with consequent induction of 
EMT and expansion of the cancer stem cell compartment 
(Figure 8).
The ETS factor ESE3/EHF is an endogenously 
expressed ETS factor whose level is higher in normal 
prostate and decreased in aggressive and metastatic tumors 
[15]. We recently reported a tumor suppressor role of 
ESE3/EHF in controlling differentiation and cancer stem-
like phenotype in human prostate epithelial cells [17]. 
ESE3/EHF loss in prostate epithelial cells leads to cell 
transformation, EMT, acquisition of stem-like properties 
and broad reprogramming of the cell transcriptome. More 
recently, we have reported that ESE3/EHF controls the 
Lin28/let-7 axis acting as a critical barrier to malignant 
transformation and preventing cancer stem cell expansion 
[18]. In this study, in an effort to further understand the 
mechanisms by which ESE3/EHF controls cancer stem-
like cells we uncovered that IL-6 is a key target repressed 
by ESE3/EHF. IL-6 is a cytokine involved in many 
pathophysiologic processes. IL-6 signals through a cell-
surface type I cytokine receptor complex. IL-6 interaction 
with the receptor triggers its activation initiating a signal 
transduction cascade leading to activation of the JAK/
STAT pathway. Several pieces of evidences have associated 
IL-6 with an aggressive prostate cancer phenotype and 
metastatic processes through the regulation of EMT and the 
homing of cancer cells to the bone [22]. Recent evidence 
indicates that IL-6 plays a major role in the transition 
from hormone-dependent to CRPC [22]. Moreover, IL-6 
is upregulated in many epithelial cancers such as breast 
and prostate [23–25]. Collectively, the evidence reported 
so far points to an important role of IL-6 in transformation 
and a stem-like phenotype in tumors. Additionally, IL-6 is 
a key molecule in the dynamic equilibrium between CSCs 
and non cancer stem cells (NCSCs) via IL-6 secretion, and 
IL-6 can convert NCSCs to CSCs in breast and prostate 
cell lines as well as from cells derived from human breast 
tumors [26]. Importantly, IL-6 has been reported as a 
key mediator of an inflammatory positive feedback loop 
occurring from non-transformed to transformed breast 
epithelial cells and involving other key oncogenic proteins 
such as NF-kB, Lin28 and STAT3 [27]. 
Thus, a deep understanding of factors regulating 
IL-6 expression might be relevant for the development 
of novel therapeutic approaches targeting its activity 
[28, 29]. We have previously reported that IL-6 is induced 
in prostate cancer cells and that the ETS factor ESE1 was 
an important mediator enhancing the NFKb response [30].
In this study we identify IL-6 as a novel direct target 
of ESE3/EHF in prostate epithelial cells. Intriguingly, 
Figure 7: IL-6 elevation and loss of ESE3/EHF are associated with STAT3 activation and inflammatory features in 
human prostate tumors. (A) Box–plots showing the level of IL-6 (left) and ESE3/EHF (right) in the selected tumor populations. 
(B) Transcription factor analysis of the top genes activated in IL-6high/ESE3low compared to all the other tumors using CHEA by Enrich. 
(C) Number of ESE3/EHF putative binding sites among the top activated genes in the IL-6high/ESE3low signature. (D) Functional annotation 
analysis by Metacore using the upregulated genes. (E) GSEA using indicated list of genes and comparing IL-6high/ESE3low with all the other 
tumors in the EHRO dataset.
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to our knowledge this is the first reported inhibitory 
transcription factor controlling IL-6. 
IL-6 expression has been reported to be inhibited 
by wild type p53 and the retinoblastoma (RB) tumor 
suppressor gene [31]. However, it is not known if the 
effect is direct or mediated by the modulation of other 
transcription factors. Future studies should address the 
possibility of a crosstalk between ESE3, Rb and p53 in 
the control of IL-6 transcription.
We have recently reported that ESE3/EHF restrains 
stemness by repressing the LIN28/let7 axis [18]. The 
data presented here establish an additional mechanism 
by which ESE3/EHF restrains stemness and tumor 
progression through repression of IL-6. On the other 
hand, elevation of IL-6 by loss of ESE3/EHF might also 
impact the activation of Lin28/let7b axis. Accordingly, 
we found that IL-6 treatment promoted transformation 
and cancer stem-like features in normal prostate epithelial 
cells. In contrast, IL-6 inhibition by siRNA reverted these 
malignant phenotypes in cancer cells. We have previously 
reported that tumors with low levels of ESE3/EHF have 
aggressive clinical characteristics and are phenotypically 
associated with EMT and cancer stem cell features.The 
data reported here support the notion that IL-6 could 
contribute to the aggressive features of these tumors and 
particularly the cancer stem like compartment. Tumors 
with low levels of ESE3/EHF might be more prone to 
an aberrant response to IL-6 stimulation. Collectively, 
these data open new perspectives to specifically target this 
group of tumors with strategies reversing IL-6 activation. 
We report here that treatment with JAK-STAT inhibitors 
prevented self-renewal in vivo in prostate epithelial cells 
with ESE3/EHF knockdown. These data are clinically 
relevant and suggest the possibility of selective targeting 
of the CSC like compartment in ESE3low tumors.
Although the use and benefit of JAK-STAT 
inhibitors has been amply reported, our data introduce a 
novel concept that targeting IL-6-JAK-STAT3 signaling 
could be more effective in tumors in which both ESE3/
EHF and IL-6 are altered. Further studies are necessary 
to demonstrate this concept. IL-6 has been shown to have 
context-dependent pro- and anti-inflammatory properties 
and this might influence greatly its oncogenic capabilities 
in different contexts [29]. Interestingly, recent data from 
our laboratory indicate that there are additional molecular 
mechanisms linking to IL-6/STAT3 activation in the context 
of ESE3/EHF loss in addition to the one described here. 
Collectively, our data support the notion that activation of 
the IL-6/STAT3 and inflammatory-like signaling leads to 
deleterious effects in normal prostate epithelial cells and 
tumors, leading to expansion of the cancer stem-like cell 
compartment and self-renewal properties. Understanding 
these mechanisms will support the possibility of targeting 
these aggressive tumors within the scope of development 
of precision medicine approaches for the prostate cancer 
management and treatment.
MATERIALS AND METHODS
Cell lines, transfection and selection of cell clones
Immortalized human prostate epithelial cells 
(PrECs) [15] and RPWE-1 with stable knockdown of 
ESE3/EHF by shRNAs were established as previously 
described [16]. LNCaP, DU145 and PC3 were obtained 
from ATCC and maintained in RPMI-1640 (Gibco) 
supplemented with 10% fetal bovine serum. DU145 cells 
expressing ESE3/EHF were generated after transfection 
with ESE3/EHF expression vector and selection with G418 
[15]. Where indicated, PrECs, RWPE-1, ESE3KD-PrECs 
Figure 8: ESE3/EHF controls the activation status of IL-6 and JAK/STAT pathway in normal prostate. Loss of ESE3/
EHF leads to upregulation of IL-6 and activation of the JAK/STAT3 pathway with consequent induction of EMT and expansion of the 
cancer stem cell compartment.
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and ESE3KD-RWPE-1 cells were stimulated with IL-6 
50 ng/mL for 2 or 4 h or DMSO as control.
RNA extraction, quantitative real-time RT-PCR 
and siRNAs
RNA was extracted by Direct-zol RNA Mini-prep kit 
(Zymo Research). Quantitative real-time RT-PCR (qRT-
PCR) was carried out using 20 ng of RNA as template for 
SYBR Green Fast One Step kit (Qiagen). qRT-PCR primers 
are reported in Supplementary Table S1. For transient gene 
knockdown cells were transfected with siRNAs directed to 
IL-6 (siRNA Silencer select, Ambion) or control (siGL3) 
siRNA [17] using jetPRIME (Polyplus).
Soft agar and in vitro prostatosphere forming 
and self-renewal assay
Soft-agar assays were performed as previously 
described [32]. The prostatosphere assay was previously 
described [17]. The sphere forming efficiency (SFE) was 
determined as percentage of prostatosphere relative to the 
number of cells plated at the start of the experiment. Each 
experiment was carried out in triplicate and repeated at 
least three times.
Reporter constructs and luciferase assays 
To analyze IL-6 activity we used IL-6 responsive 
luciferase reporter pGL3-basic-IL-6 provided by W. 
Farrar [33]. Luciferase reporter assays were performed 
as previously described [17]. Results were normalized to 
Renilla luciferase and expressed as Relative Luciferase 
Activity (RLA). Each experiment was performed in 
triplicate and repeated at least three times.
Animals and tumor xenografts
Mice were purchased from the Harlan Laboratories. 
Mice were maintained under pathogen-free conditions 
with food and water provided ad libitum and their 
general health status was monitored daily. All protocols 
involving animals were conducted in conformity with the 
institutional guidelines for animal experimentation and in 
compliance with national and international policies. Study 
protocol was approved by the Swiss Veterinary Authority. 
For in vivo self-renewal experiments prostatosphere-
derived ESE3KD-PrECs cells (2 × 105 cells/site) were 
inoculated with Matrigel in the flank of NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (n = 4/ group). 
Tumor size was monitored twice a week with caliper. 
Primary tumor xenografts derived from ESE3KD-
PrECs prostatospheres were dissociated into single cell 
suspensions and implanted subcutaneously with Matrigel 
(2 × 105 cells/site) in NSG mice for two more generations 
(n = 4/group). For systemic treatment with JAK-STAT 
inhibitor (NVP), mice were injected with a dose of 
100 mg/kg of NVP-BSK805 by oral gavage every two 
days for 4 weeks [34, 35].
Immunoblot and immunocytochemistry
Immunoblots were carried out using anti-IL-6 
Rabbit Polyclonal antibody (NeoBioLab),1:500 in I-block 
and tubulin as control as previously described (Albino et 
al., 2016). For immunocytochemistry (ICC), harvested 
cells were washed in PBS by centrifugation and then the 
concentration adjusted to 5 × 106 cells/ml in PBS. Cells 
were attached to slides using Cytospin Cytocentifuge 
(Thermo Scientific) at 800 rpm for 4 minutes. Cells were 
fixed and permeabilized with Acetone:Methanol, 1:1. 
After blocking with 5% BSA cells were incubated with 
anti-STAT3 total (Cell Signaling #9139) 1:400, and anti-
STAT3 TYR705 (Cell Signaling #9145) 1:400, antibodies. 
Cell nuclei were counterstained with hematoxylin solution 
and finally, the sections were dehydrated and mounted in a 
suitable organic mounting medium. 
Flow cytometry
All steps for flow cytometry were performed in 
PBS supplemented with 0.5% BSA, and 2 mM EDTA. 
STAT3-TYR705 was purchased from Bioconcept (Anti-
human Phospho-Stat3 /D3A7) alexa 647, cat. #4324) and 
used for analysis in accordance with the manufacturer’s 
instructions. Cell sorting was performed with a FACSAria 
III sorter (BD Biosciences).
Chromatin immunoprecipitation
Computational search for ETS binding sites on 
selected gene promoters was performed using Motifviz 
(biowulf.bu.edu/MotifViz). Chromatin immunoprecipitation 
was performed with anti-ESE3 (Clone 5A5.5, Lab Vision, 
Fremont, CA USA); anti AcH3 (Upstate, Millipore); 
anti H3K9 2met (Upstate, Millipore); anti H3K27 3met 
(Upstate, Millipore) and IgG control antibody. Samples 
were analyzed as previously described [16] by qRT-PCR. 
Primer sets are reported in Supplementary Table S1.
Correlation analysis, gene signature, functional 
annotation and gene set enrichment analysis (GSEA)
The EHRO, Taylor and Grasso [20, 21, 36] human 
prostate cancer datasets were retrieved from GEO. 
Only raw intensity data for prostate cancer samples 
were considered. Data were processed in R using the 
Bioconductor package “oligo” for Affymetrix arrays: 
sets were separately RMA (Robust Multi-Array Average) 
normalized (with background correction) and quantile 
normalized at the probe level. Log2, normalized expression 
values for ESE3/EHF and IL-6 genes were extracted and 
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their correlation was tested by Pearson’s product moment 
correlation coefficient. Genes were centered and scaled. 
Scatter plots of ESE3/EHF vs IL-6 have been drawn 
and lines of best fit calculated. Correlation analysis was 
performed in indicated human prostate cancer datasets. 
Pearson test was used, which estimates a correlation value 
“r” and a significance p-val (r > 0 < 1, direct correlation; r 
< 0 > –1, inverse correlation).
To extract the gene signature, expression of genes 
EHF and IL-6 was dichotomized based on the following 
threshold (for EHF 25th percentile and for IL-6 75th 
percentile). Samples with low EHF and high IL-6 (n = 51, 
Ehro et al., 2013) were selected and compared to all the 
others (n = 494, Ehro et al., 2013) by t-test and results 
were retained if FDR (False Discovery Rate) < 0.05. The 
resulted lists of genes were then divided into activated 
and repressed genes respectively. Transcription factor 
analysis was carried using Enrich. For ETS occupancy 
we used published ChIP-Seq data for EHF in CALU3 
cells [37] and ERG in VCaP / LNCaP [38]. The ChIP-
Seq data was annotated using gencode-v19 human 
genome database. Functional annotation of the genes 
significantly deregulated in IL-6high/ESE3low was obtained 
using metacore tools. GSEA software was used to identify 
groups of functionally related genes. Gene sets with an 
FDR < 0.05 were considered significant. The gene ranking 
metric in the weighted enrichment score was SNR (signal-
to-noise ratio), and P values were calculated using 1000 
permutations of the genes.
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